EcoR1 Capital, LLC
Annual return '25
+14.3%
SPY '25
+17.7%
Alpha
-3.5ptsvs SPY
Invested
$2.4B
Holdings
29
Trades YTD
0
Performance · Fund vs SPY
Cumulative return · quarterly snapshotsCoverage 99%. 4 quarters of 2025 measured against SPY adj-close benchmark.
Top holdings · current snapshot
Source: 13F-HR01
$ZYME
ZYMEWORKS INC
Q2 2025: Increased +33.1% (17.26M → 22.97M shares)
24.4%
02
$ANAB
ANAPTYSBIO INC
Q4 2024: New position (7.87M shares)
18.5%
03
$JAZZ
JAZZ PHARMACEUTICALS PLC
Q4 2024: New position (1.71M shares)
13.7%
04
$CNTA
CENTESSA PHARMACEUTICALS PLC
Q3 2025: New position (550.0k shares)
10.8%
05
$CRNX
CRINETICS PHARMACEUTICALS IN
Q4 2024: New position (4.29M shares)
6.6%
06
$AKTS
AKTIS ONCOLOGY INC
Held since at least Q1 2024
3.7%
07
$ORIC
ORIC PHARMACEUTICALS INC
Q3 2025: Increased +315.8% (1.62M → 6.73M shares)
3.6%
08
$CGON
CG ONCOLOGY INC
Held since at least Q1 2024
3.2%
09
$CRSP
CRISPR THERAPEUTICS AG
Q4 2024: New position (1.39M shares)
2.8%
10
$ETON
ETON PHARMACEUTICALS INC
Q2 2025: Increased +1910.4% (101.0k → 2.03M shares)
2.3%
Recent trades · Last 90 days
No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.
Convergence · Pattern Engine ships in v1.1
30-day windowIn development
Convergence participation lands with the Pattern Engine.
Once the Pattern Engine ships, this section will list every active convergence event this fund is named in — with the other named funds, the Congress members on the same name, and combined position size.
Source data: SEC EDGAR · 13F-HR filings · Performance through 2025-12-31 · Last refreshed 08:09 UTC.